Table 2.
Summary of Results of the Included Studies Reporting on Active Case Finding for Sexually Transmitted Infections, 1990–February 2016a
| Region | Reference | Testing Modality | Chlamydia/Gonorrhea/Trichomoniasis | Syphilis | ||||
|---|---|---|---|---|---|---|---|---|
| Uptake, % | Chlamydia Positivity Rate, % | Gonorrhea Positivity Rate, % | Trichomoniasis Positivity Rate, % | Uptake, % | Positivity Rate, % | |||
| EU/EEA | Foschi, 2015 (43) | At entry; opt in | 65.8 | 3.6 | ||||
| Non–EU/EEA | Arriola, 2001 (46) | At entry; opt in | NR | 6.5 | 3.10 | NR | 2.0 | |
| Non–EU/EEA | Franklin, 2012 (85) | At entry; opt in | 100.0 | 6.4 | 0.9 | |||
| Non–EU/EEA | Heimberger, 1993 (54) | At entry; opt in | 77.0 | 2.6 | ||||
| Non–EU/EEA | Kahn, 2002 (55) | At entry; opt in | 76.0 | 6.0 | ||||
| Non–EU/EEA | Mertz, 2002 (90) | At entry; opt in | 100.0 | NR | NR | |||
| Non–EU/EEA | Roth, 2011 (88) | At entry; opt in | NR | 44.0 | ||||
| Non–EU/EEA | Silberstein, 2000 (56) | At entry; opt in | 69.0 | 1.4 | ||||
| Non–EU/EEA | Cole, 2014 (31) | At entry; opt out | 78.1 | 2.5 | 7.6 | |||
| Non–EU/EEA | Shaikh, 2015 (29) | At entry; opt out | NR | 9.3 | 1.3 | |||
| EU/EEA | Babudieri, 2012 (61) | During stay | 56.3 | 2.3 | ||||
| EU/EEA | Lopez-Corbeto, 2012 (76) | During stay | NR | 11.0 | ||||
| EU/EEA | Sagnelli, 2012 (75) | During stay | 55.7 | 2.1 | ||||
| EU/EEA | Torrez, 2010 (78) | During stay | 98.4 | 6.0 | 2.0 | |||
| Non–EU/EEA | Brown, 2014 (30) | During stay | NR | 5.3 | 0.8 | |||
| Non–EU/EEA | Newman, 2003 (77) | During stay | 82.1 | NR | ||||
| Non–EU/EEA | Shaikh, 2015 (29) | During stay | NR | 5.6 | 0.9 | |||
| Non–EU/EEA | Sieck, 2011 (83) | At release | 37.6 | 0.6 | 0.0 | 5.5 | NR | 0.1 |
Abbreviations: EEA, European Economic Area; EU, European Union; NR, not reported.
a The date range was 1980–February 2016 for the Cochrane Database.